Lundbeck Appoints Markus Kede as Their New Chief AI Officer

H. Lundbeck A/S Names New Chief AI Officer

In a significant development for the biopharmaceutical industry, H. Lundbeck A/S has revealed the appointment of Markus Kede as their new Senior Vice President and Chief AI Officer. This change, announced on March 10, 2026, underscores Lundbeck's commitment to integrating artificial intelligence into its operations as a key element of their Focused Innovator Strategy.

Markus Kede, who is set to join Lundbeck's Executive Leadership Team, will report directly to Charl van Zyl, the President and CEO. This new role signifies a major step for Lundbeck as they aim to transition into a bionic company, leveraging AI to enhance their operational capabilities and maximize patient care outcomes.

Charl van Zyl explained, "As we advance our Focused Innovator strategy, becoming a bionic company is one of our key strategic focuses. AI is not merely about adopting technology; it’s a fundamental transformation in our approach to thinking, decision-making, and execution across every facet of our organization. Markus brings the essential experience and vision needed to implement AI in a thoughtful and impactful manner."

Kede's career thus far has been marked by a successful tenure of over 15 years in various global and commercial leadership roles, particularly within highly regulated markets. Prior to this appointment, Kede served as Senior Vice President of Finance and Business Planning at Lundbeck US. In that capacity, he has played an instrumental role in driving strategic initiatives aimed at embedding AI and automating processes across the company.

Under Kede's leadership, Lundbeck has already fostered fruitful collaborations with notable organizations such as OpenAI, Iambic Therapeutics, and the Danish Centre for AI Innovation. These partnerships have propelled Lundbeck's research efforts towards discovering new drug candidates and have improved operational execution through enhanced data analytics and customer engagement efforts.

In his new position, Kede will be tasked with not only steering Lundbeck's global AI strategy but also establishing robust governance frameworks and responsible practices for AI implementation. He aims to build specialized AI capabilities and drive scalable applications of AI across various functions within the company. With a focus on prioritization and measurable value creation, his initiatives will be critical in bolstering Lundbeck's competitiveness in the long run.

Markus Kede is expected to transition from his current role in the United States to his new responsibilities by July 1, 2026. His proven track record in managing strategic and financial performance will be vital as Lundbeck seeks to innovate and maintain its industry position.

Lundbeck is renowned for focusing exclusively on brain health and has over 70 years of expertise in neuroscience. With the increasing understanding of the complexities of brain disorders, the company is dedicated to exploring new therapeutic avenues and formulating effective treatments for patients who currently have limited options. Their resolve to tackle stigma and increase health equity also highlights Lundbeck's broader mission of providing long-term value not only to shareholders but to the global community at large.

With over 5,000 employees spanning across 20 countries and products available in more than 80 nations, Lundbeck's latest move underlines its aspirations to harness the transformative potential of AI in reshaping the future of healthcare. For further details, interested parties can explore Lundbeck's corporate site for more information about their strategies and commitment to brain health.